Status:
COMPLETED
A Study of LY2409021 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy Participants
Eligibility:
All Genders
18-85 years
Phase:
PHASE1
Brief Summary
The study involves a single dose of LY2409021 taken by mouth. The purpose of this study is to determine how much LY2409021 enters the bloodstream and how long the body takes to get rid of the drug aft...
Eligibility Criteria
Inclusion
- Healthy males or females as determined by medical history
- Satisfactory clinical laboratory and physical examination tests
- Have a body mass index (BMI) of 18 to 32.0 kilograms per meter squared (kg/m\^2)
Exclusion
- \- Abnormal electrocardiograms (ECGs)
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT02217618
Start Date
August 1 2014
End Date
September 1 2014
Last Update
October 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Daytona Beach, Florida, United States